Cosentyx's Effect on Vaccines
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system. This can weaken vaccine responses, especially live vaccines, which are contraindicated during treatment.[1]
Recommended Gap Before Starting Cosentyx
Complete all vaccinations at least 4 weeks before the first Cosentyx dose. This ensures optimal immune response, as the drug's immunosuppressive effects begin soon after injection.[1][2]
Recommended Gap After Starting Cosentyx
Hold Cosentyx for at least 4 weeks after any live vaccine. For inactivated or mRNA vaccines (e.g., COVID-19, flu shots), experts recommend a 4-week gap in either direction—avoid vaccinating within 4 weeks before or after a dose—to maximize antibody production.[1][3]
Live vs. Inactivated Vaccines
- Live vaccines (e.g., MMR, varicella, oral polio, yellow fever): Avoid entirely while on Cosentyx and for weeks after stopping. Risk of infection from the live virus increases.
- Inactivated/non-live vaccines (e.g., Tdap, pneumococcal, shingles recombinant like Shingrix, COVID-19): Safe but less effective; time them 4 weeks apart from doses.[1][2]
Why the 4-Week Rule?
IL-17 inhibition peaks within days but full effects last weeks. Studies show reduced vaccine efficacy (e.g., 20-50% lower antibody titers for flu or pneumococcal shots) if timed too closely.[3][4] Novartis, the manufacturer, and rheumatology guidelines align on this spacing.[1]
Patient Scenarios and Exceptions